103 related articles for article (PubMed ID: 11219329)
1. Individualizing therapy for early, middle-of-the-night and late-night insomnia.
Scharf MB
Int J Clin Pract Suppl; 2001 Jan; (116):20-4. PubMed ID: 11219329
[TBL] [Abstract][Full Text] [Related]
2. Treatment of insomnia with zaleplon, a novel sleep medication.
Doghramji PP
Int J Clin Pract; 2001 Jun; 55(5):329-34. PubMed ID: 11452683
[TBL] [Abstract][Full Text] [Related]
3. Zaleplon: a review of its use in the treatment of insomnia.
Dooley M; Plosker GL
Drugs; 2000 Aug; 60(2):413-45. PubMed ID: 10983740
[TBL] [Abstract][Full Text] [Related]
4. Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon.
Stone BM; Turner C; Mills SL; Paty I; Patat A; Darwish M; Danjou P
Br J Clin Pharmacol; 2002 Feb; 53(2):196-202. PubMed ID: 11851645
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of zaleplon at peak plasma levels.
Mangano RM
Int J Clin Pract Suppl; 2001 Jan; (116):9-13. PubMed ID: 11219331
[TBL] [Abstract][Full Text] [Related]
6. Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia.
Weitzel KW; Wickman JM; Augustin SG; Strom JG
Clin Ther; 2000 Nov; 22(11):1254-67. PubMed ID: 11117652
[TBL] [Abstract][Full Text] [Related]
7. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group.
Fry J; Scharf M; Mangano R; Fujimori M
Int Clin Psychopharmacol; 2000 May; 15(3):141-52. PubMed ID: 10870872
[TBL] [Abstract][Full Text] [Related]
8. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group.
Hedner J; Yaeche R; Emilien G; Farr I; Salinas E
Int J Geriatr Psychiatry; 2000 Aug; 15(8):704-12. PubMed ID: 10960882
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
Scharf MB; Roth T; Vogel GW; Walsh JK
J Clin Psychiatry; 1994 May; 55(5):192-9. PubMed ID: 8071269
[TBL] [Abstract][Full Text] [Related]
10. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia.
Walsh JK; Pollak CP; Scharf MB; Schweitzer PK; Vogel GW
Clin Neuropharmacol; 2000; 23(1):17-21. PubMed ID: 10682226
[TBL] [Abstract][Full Text] [Related]
11. The need for flexibility in dosing of hypnotic agents.
Doghramji K
Sleep; 2000 Feb; 23 Suppl 1():S16-20; discussion S21-2. PubMed ID: 10755804
[TBL] [Abstract][Full Text] [Related]
12. Implications of hypnotic flexibility on patterns of clinical use.
Lader MH
Int J Clin Pract Suppl; 2001 Jan; (116):14-9. PubMed ID: 11219327
[TBL] [Abstract][Full Text] [Related]
13. Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy.
Belleville G; Morin CM
Health Psychol; 2008 Mar; 27(2):239-48. PubMed ID: 18377143
[TBL] [Abstract][Full Text] [Related]
14. Treatment for insomnia.
Finucane TE
Lancet; 2002 Apr; 359(9315):1434; author reply 1434. PubMed ID: 11978363
[No Abstract] [Full Text] [Related]
15. Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent.
Patat A; Paty I; Hindmarch I
Hum Psychopharmacol; 2001 Jul; 16(5):369-392. PubMed ID: 12404558
[TBL] [Abstract][Full Text] [Related]
16. The relationship between psychiatric diseases and insomnia.
Roth T
Int J Clin Pract Suppl; 2001 Jan; (116):3-8. PubMed ID: 11219330
[TBL] [Abstract][Full Text] [Related]
17. Middle-of-the-night hypnotic use in a large national health plan.
Roth T; Berglund P; Shahly V; Shillington AC; Stephenson JJ; Kessler RC
J Clin Sleep Med; 2013 Jul; 9(7):661-8. PubMed ID: 23853559
[TBL] [Abstract][Full Text] [Related]
18. Main neuroendocrine features and therapy in primary sleep troubles.
Amihăesei IC; Mungiu OC
Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):862-6. PubMed ID: 23272543
[TBL] [Abstract][Full Text] [Related]
19. Benefit-risk assessment of zaleplon in the treatment of insomnia.
Barbera J; Shapiro C
Drug Saf; 2005; 28(4):301-18. PubMed ID: 15783240
[TBL] [Abstract][Full Text] [Related]
20. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
